Место арГПП-1 и иНГЛТ-2 в современной терапии сахарного диабета 2 типа


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

В статье рассмотрены современные подходы к терапии больных сахарным диабетом 2 типа (СД2) с использованием немедикаментозных и лекарственных методов лечения. Проблема лечения СД в современном мире не теряет актуальности. Ежегодно обновляются рекомендации по инициации и интенсификации терапии пациентов с СД2. Представлены основные этапы применения сахароснижающих препаратов.

Полный текст

Доступ закрыт

Об авторах

Михаил Борисович Анциферов

ГБУЗ «Эндокринологический диспансер» ДЗМ

Email: antsiferov@rambler.ru
д.м.н., профессор, президент Москва, Россия

О. М Котешкова

ГБУЗ «Эндокринологический диспансер» ДЗМ

Москва, Россия

О. В Духарева

ГБУЗ «Эндокринологический диспансер» ДЗМ

Москва, Россия

Н. А Демидов

Городская больница г. Московский ДЗМ

Москва, Россия

М. С Новикова

ГБУЗ «Эндокринологический диспансер» ДЗМ

Москва, Россия

Список литературы

  1. www.diabetesatlas.org. Facts & figures (idf.org). URL: https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html
  2. Davies M.J., Arora V.R., Vanita R., et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetol. 2022;65,1925-66. doi: 10.1007/s00125-022-05787-2.
  3. Breslin M., Mullan R.J., Montori V.M. The design of a decision aid about diabetes medications for use during the consultation with patients with type 2 diabetes. Patient Educ Couns. 2008;73:465-72. doi: 10.1016/j.pec.2008.07.024.
  4. Lingvay I., Sumithran P., Cohen R.V., le Roux C.W. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399: 394-405. doi: 10.1016/S0140-6736(21)01919-X.
  5. Riddle M.C., Cefalu W.T., Evans P.H., et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diab Care. 2021;44:2438-44. doi: 10.2337/dci21-0034.
  6. Schwingshackl L., Chaimani A., Hoffmann G, et al.Network meta-analysis on the comparative efficacy of different dietary approaches on glycaemic control in patients with type 2 diabetes mellitus. Eur J Epidemiol. 2018;33:157-70. doi: 10.1007/s10654-017-0352-x.
  7. Estruch R, Ros E., Salas-Salvado J., et al. PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378:e3476,77. doi: 10.1056/NEJMoa1800389.
  8. Lean M.E., Leslie W.S., Barnes A.C., etal. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391:541-51. doi: 10.1016/S0140-6736(17)33 1 02-1.
  9. Lean M.E.J., Leslie W.S., Barnes A.C., et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet. Diab Endocrinol. 2019;7:344-55. Doi: 10.1016/ S2213-8587(19)30068-3.
  10. Delevatti R.S., Bracht C.G., Lisboa S.D.C., et al. The role of aerobic training variables progression on glycemic control of patients with type 2 diabetes: a systematic review with meta-analysis. Sports Med Open. 2019;5:22. doi: 10.1186/s40798-019-0194-z.
  11. Lalau J.D., Kajbaf F., Bennis Y., et al. Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diab Care. 2018;41:547-53. doi: 10.2337/dc17-2231.
  12. Nauck M.A., Quast D.R., Wefers J., Meier J.J. GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art. Mol Metab. 2021;46:101102. Doi: 10.1016/j. molmet.2020.101102.
  13. Frias J.P., Bonora E., Nevarez Ruiz L., et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diab Care. 2021;44:765-73. doi: 10.2337/dc20-1473.
  14. Frias J.P, Auerbach P, Bajaj H.S., et al. Efficacy and safety of once-weekly semaglutide 2*0 mg versus 1*0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet. Diab. Endocrinol. 2021;9:563-74. doi: 10.1016/S2213-8587(21) 00174-1.
  15. Bethel M.A., Diaz R, Castellana N., et al. HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression. Diab Care. 2021;44(1):290-96. doi: 10.2337/dc20-1815.
  16. Heerspink H.J.L., Stefansson B.V., Correa-Rotter R., et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-46. doi: 10.1056/NEJMoa2024816.
  17. Kosiborod M.N., Esterline R., Furtado R.H.M., et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. Diab Endocrinol. 2021;9:586-94. doi: 10.1016/S2213- 8587(21)00180-7.
  18. Cannon C.P, Pratley R., Dagogo-Jack S., et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425-35. doi: 10.1056/NEJMoa2004967.
  19. Heerspink H.J.L., Jongs N., Chertow G.M., et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Randomized Controlled Trial. Lancet. Diab Endocrinol. 2021;9(11):743-54. Doi: 10.1016/ S2213-8587(21)00242-4.
  20. Packer M., Anker S.D., Butler J., et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-24. doi: 10.1056/NEJMoa2022190.
  21. Shaman A.M., Bain S.C., Bakris G.L., et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation. 2022;145:575-85. Doi: 10.1161/ CIRCULATIONAHA.121.055459.
  22. Sattar N., Lee M.M.Y., Kristensen S.L., et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and metaanalysis of randomised trials. Lancet. Diab Endocrinol. 2021;9:653-62. Doi: 0.1016/ S2213-8587(21)00203-5.
  23. Neuen B.L., Young T, Heerspink H.J.L., et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet. Diab Endocrinol. 2019;7:845-54. Doi: 10.1016/ S2213-8587(19)30256-6.
  24. Neuen B.L., Arnott C., Perkovic V., et al. Sodium-glucose co-transporter-2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes. Diab Obes Metab. 2021;23:382-90. doi: 10.1111/dom.14226.
  25. Tsapas A., Karagiannis T., Avgerinos I., et al. GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. Diab Res Clin Pract. 2021;177:108921. doi: 10.1016/j.diabres.2021.108921.
  26. Lavalle-Cobo A., Masson W., Lobo M., et al. Glucagon-like peptide-1 receptor agonists and cardioprotective benefit in patients with type 2 diabetes without baseline metformin: a systematic review and update meta-analysis. High Blood Press Cardiovasc Prev. 2021;28:605-12. doi: 10.1007/s40292-021-00479-1.
  27. Palmer S.C., Tendal B., Mustafa R.A., et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m45 73. doi: 10.1136/bmj.m4573.
  28. Lin D.S.H., Lee J.K., Hung C.S., Chen W.J. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. Diabetol. 2021;64:2676-86. doi: 10.1007/s00125-021-05529-w.
  29. Patorno E., Htoo P.T., Glynn R.J., et al. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med. 2021;174:1528-41. doi: 10.7326/M21-0893.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2022

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах